Skip to content
DataLookout
Menu

NCT06712654

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Study completion pushed from Mar 31, 2027 to Apr 30, 2028
    • Interventions modified
    • Trial arms changed: 7 → 8
  2. Minor Study sites revised (31)v12
  3. Minor Study sites revised (31)v11
  4. Minor Study sites revised (31)v10
  5. Minor Study sites revised (31)v9
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Study sites revised (31)v8
  2. Minor Study sites: 30 to 31v7
  1. Minor Trial sites expanded: 26 → 30 locationsv6
  2. Notable Recruitment opened
    • Site details revised at 5 of 26 sites
    v5
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 31, 2026 to Jun 1, 2026
    • Site details revised at 26 of 26 sites
    v4
  4. Minor Trial sites expanded: 0 → 26 locationsv3
  5. Notable Lead sponsor: Alebund Pharmaceuticals to R1 Therapeuticsv2 Show 12 more changesShow less
    • Primary completion date: Nov 30, 2025 to Feb 28, 2027
    • Start date: Apr 10, 2025 to May 31, 2026
    • Eligibility criteria expanded, about 58 words
    • Primary endpoint revised
    • Enrollment target: 144 to 168
    • Study completion date: Dec 30, 2025 to Mar 31, 2027
    • Interventions: AP306 100mg TID (Drug), AP306 125mg BID (Drug), AP306 125mg TID (Drug), AP306 150mg BID (Drug), AP306 75mg TID (Drug), Placebo TID (Drug) to AP306 100 mg TID (Drug), AP306 125 mg BID (Drug), AP306 125 mg TID (Drug), AP306 150 mg BID (Drug), AP306 75 mg BID (Drug), AP306 75 mg TID…
    • Secondary endpoints expanded, about 39 words
    • Study description expanded, about 102 words
    • Study arms: 2 to 7
    • Collaborators expanded, about 2 words
    • Study title expanded, about 1 word
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To investigate the ability of AP306 at different fixed doses to lower serum phosphate in participants with hyperphosphatemia receiving maintenance hemodialysis
Timeframe: 8 weeks

Secondary (3)

To assess the proportion of participants with serum phosphate in the target range
To assess the change in serum phosphate from baseline to the end of the Treatment Period
To assess the time to response on serum phosphate reduction

Arms and interventions

Cohort 1Experimental
Cohort 2Experimental
Cohort 3Experimental
Cohort 4Experimental
Cohort 5Experimental
Cohort 6Experimental
Cohort 7Placebo comparator
Open-Label Extension (US Only)Experimental

Drugs: AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID, AP306 75 mg TID, AP306 100 mg TID, AP306 125 mg TID, Placebo, AP306 (open-label, dose titration)

Sites

31 sites in 2 countries

United States 24, China 7